Similarly, an increase in cognitive performance upon EPO in patients with chronic progressive multiple sclerosis occurred independently of changes in hemoglobin levels, and persisted for months after termination of EPO treatment [4,19]. The gene discussed is EPO; the disease is chronic progressive multiple sclerosis.